Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia

Aslan, B; Kismali, G; Iles, LR; Manyam, GC; Ayres, ML; Chen, LS; Gagea, M; Bertilaccio, MTS; Wierda, WG; Gandhi, V

Gandhi, V (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA.;Gandhi, V (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.

BLOOD CANCER JOURNAL, 2022; 12 (5):

Abstract

Pirtobrutinib (LOXO-305), a reversible inhibitor of Bruton's tyrosine kinase (BTK), was designed as an alternative strategy to treat ibrutinib-resista......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索